Denmark-based ExpreS2ion Biotechnologies has executed a non-exclusive research license agreement with Boston Children’s Hospital (Boston Children’s) to use its recombinant protein expression platform ExpreS2 for the hospital’s academic research.

Boston Children’s is the paediatric teaching affiliate of Harvard Medical School.

The ExpreS2 platform is being used to solve protein expression challenges and has proven to be instrumental in advancing research in neglected diseases, including malaria research and vaccine projects.

The system offers high quality, homogenous expressed proteins, qualities that are needed in structural biology studies.

"Our proprietary technology platform can deliver protein for laboratory use and is also compatible with current good manufacturing practices (cGMP)."

ExpreS2 is instrumental in advancing research for these neglected diseases where other expression systems failed to yield native properties of the parasite proteins or even failed to express the proteins.

ExpreS2ion chief scientific officer Wian de Jongh said: "ExpreS2ion aims to support the development of novel drugs through solving protein production challenges.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Our proprietary technology platform can deliver protein for laboratory use and is also compatible with current good manufacturing practices (cGMP).

"This interaction with Boston Children’s is part of our strategy to support top academic teams in protein expression. It is our hope that this license will advance the understanding of relevant immunological processes and of malaria vaccine candidates."

Last month, Boston Children’s selected VitalHealth Software’s QuestLink for the implementation of the International Consortium for Health Outcomes Measurement (ICHOM) standard set for cleft lip and palate.

ICHOM certified QuestLink to support the efficient gathering of patient reported outcomes (PROs) included in its standard sets.

Starting this month, the hospital will implement QuestLink, making it the first children’s hospital in the US to collect ICHOM standard sets electronically.